Expertise in
4
conditions

Gavin M. Marx

185 Fox Valley Road, 
Wahroonga, NSW, AU 
Expertise in
4
conditions
185 Fox Valley Road, 
Wahroonga, NSW, AU 

Overview

Gavin Marx practices practicing medicine in Wahroonga, Australia.

Mr. Marx is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Diarrhea, Sepsis, Breast Cancer, and Hormone Replacement Therapy (HRT).

He is actively involved in clinical research, co-authoring 60 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

185 Fox Valley Road, Wahroonga, NSW 2076, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase Ib/II Study of Intra-Arterial Liver Isolation Chemotherapy in Patients With Hepatic Metastases From Colorectal Cancer
Phase Ib/II Study of Intra-Arterial Liver Isolation Chemotherapy in Patients With Hepatic Metastases From Colorectal Cancer
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Enzalutamide, Non-Steroidal Anti Androgen, Luteinizing Hormone Releasing Hormone Analog or Surgical Castration
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial
Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial
Enrollment Status: Unknown
Publish Date: June 18, 2023
Intervention Type: Drug, Biological
Study Drugs: Bacillus of Calmette-Guerin, Mitomycin C
Study Phase: Phase 3
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Drugs: GSK525762, Abiraterone, Enzalutamide, Prednisone
Study Phase: Phase 1
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

60 Total Publications

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.
Journal: The Journal of urology
Published: July 09, 2026

Frequently Asked Questions about Gavin M. Marx

Is Gavin M. Marx a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Gavin M. Marx is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gavin M. Marx participate in research or clinical trials?

Yes. Gavin M. Marx has published 60 articles and abstracts on conditions like Prostate Cancer. You can view a list of Gavin M. Marx's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Marx's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile